Parathyroid Hormone
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Parathyroid Hormone: From Unspecified Original Indication to Migraine Disorder
One-Sentence Summary
Parathyroid hormone (DrugBank ID DB05829) has no marketing authorization or approved indication recorded in this evidence pack (0 EU licenses, market status “not marketed”). The TxGNN model predicts it may be relevant to Migraine Disorder, but this is currently supported by only 1 loosely related clinical trial and 6 publications, most of which do not directly test PTH as a therapeutic intervention for migraine.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no marketing authorization or approved indication text in the evidence pack |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for parathyroid hormone in this evidence pack, and no original approved indication is on record — the drug is currently not marketed and holds no licenses in the dataset used to generate this report. This means the usual comparison between original indication mechanism and new indication mechanism cannot be made with confidence.
The supporting rationale from the prediction itself is mixed. One 2025 genetic/cohort study identifies PTHrP (parathyroid hormone-related peptide) receptors as a candidate genetic driver of migraine susceptibility, and a 1986 paper describes central nervous system effects of parathormone — both suggest a plausible receptor-level mechanistic link. However, the majority of the associated literature (vitamin D deficiency, magnesium deficiency, MS-related bone/autonomic dysfunction) does not test PTH directly and is only tangentially connected to the migraine indication. The single associated clinical trial (foot reflexology massage for migraine) was flagged as unrelated to any pharmacological intervention.
Given this, the mechanistic link should be treated as an early-stage hypothesis derived largely from genetic association data rather than established pharmacology — consistent with the L4 (preclinical/mechanism-level) evidence classification and the “Hold” recommendation already assigned to this candidate.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07028684 | N/A | Recruiting | 20 | Studies foot reflexology massage for pain/sleep/quality of life in women with migraine — non-pharmacological, not a test of PTH; flagged as an unrelated mismatch (relevance grade C) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24714817 | 2014 | RCT | Braz J Med Biol Res | Vitamin D add-on to amitriptyline reduced pediatric migraine attack frequency; does not test PTH directly |
| 40297711 | 2025 | Genetic/Cohort | Brain Communications | Identifies PTHrP receptor genes as candidate genetic drivers of migraine susceptibility — association study, not a treatment trial |
| 31261815 | 2019 | Cohort | Medicina (Kaunas) | Evaluates vitamin D levels and response to therapy in childhood migraine; PTH not directly assessed |
| 29429076 | 2018 | Review | Neuromolecular Medicine | Reviews cardiovascular autonomic dysfunction linking MS, osteoporosis and neurodegeneration; tangential to PTH-bone axis |
| 11425281 | 2001 | Review | Medical Hypotheses | Broad review of magnesium deficiency pathology across many conditions; not PTH-specific |
| 3739765 | 1986 | Preclinical/Old | Acta Neurologica | Old study on central effects of calcitonin and parathormone; no abstract available |
EU Market Information
No marketing authorizations for parathyroid hormone are recorded in this evidence pack (0 licenses, status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information. No key warnings, contraindications, or drug-drug interaction data were available in this evidence pack; a summary product characteristics (SmPC) may not yet exist given the drug’s unmarketed status.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic case for PTH in migraine rests on a single genetic association study and one decades-old preclinical paper, with no clinical trial evidence directly testing PTH for this indication. Combined with the absence of any EU marketing authorization, original indication data, or MOA information, the evidence does not currently support progression.
To proceed, the following is needed:
- Confirmed original indication(s) and regulatory status for parathyroid hormone (currently absent from the evidence pack)
- Mechanism of action (MOA) data (DrugBank query pending — flagged as a High-severity data gap, DG002)
- Product safety information / SmPC warnings and contraindications (flagged as a Blocking data gap, DG001, required before any S1 safety review)
- A dedicated search for clinical or preclinical studies testing PTH/PTHrP-pathway agents specifically as migraine therapeutics, rather than as biomarkers or incidental correlates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.